The GLP Decision: A Science-Backed Comparison of Retatrutide, Semaglutide, and Tirzepatide — and How to Choose (or Wait)

You're standing in front of three doors, and everyone online seems to have a strong opinion about which one is yours.

One medication is available at your pharmacy right now. Another is available too, priced differently, dosed differently, with its own side-effect profile. A third — the one with the biggest headline numbers — isn't approved yet, and won't be for a while, though that hasn't stopped a shadow market from selling it anyway. Meanwhile you're the one who actually has to decide, with your labs, your insurance, your history, and your patience for uncertainty all pulling in different directions.

This book won't tell you which drug to choose. No book honestly can — that decision belongs to you and your doctor. What it will do is hand you the actual data, organized honestly, stripped of the marketing gloss and the anecdote-stacking that dominates so much of what you'll find searching this topic at midnight.

Inside, you'll find:

- How these drugs actually work, explained plainly — the real mechanical difference between single-receptor, dual-receptor, and triple-receptor agonism, and why it matters for both results and side effects

- The trial data, side by side — real efficacy figures from the actual named trials, with honest caveats about why comparing results across separate trials isn't as simple as lining up two percentages

- Side effects and safety, class by class — what's genuinely different between these medications and what's shared across the whole drug class

- What's available today — realistic cost, insurance navigation, and what actually starting looks like this week, not hypothetically

- The newest option's real timeline — regulatory status, what's still pending, and the one legitimate path to access it before approval

- The compounding reality, addressed directly — a plain, non-euphemistic look at the risks of the unregulated supply chain a large share of current users rely on, with zero how-to content and zero sourcing guidance, because that isn't this book's job

- A real decision framework — built around your own urgency, risk tolerance, and access situation, not a generic one-size-fits-all recommendation

- What switching actually involves, if and when your situation changes

- Where this entire drug class is headed — oral formulations, next-generation agonists, and the bigger picture past this year's headlines

This is the book for the reader who hasn't decided anything yet — who wants the real comparison before committing to any one path, grounded in named trials and current regulatory reality rather than brand marketing or forum anecdotes.

If you're tired of getting either a sales pitch or a wall of jargon every time you search this topic, this is the version written for the actual decision in front of you.